Drug Trial Radar · NCT01969643
A Safety Study of SGN-LIV1A in Breast Cancer Patients
Last checked: Nov 19, 2026Latest source record: Mar 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
290
Actual
Start
Oct 22, 2013
Primary completion
Feb 4, 2023
Study completion Feb 4, 2023
Sponsor
- Lead sponsor
- Seagen Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 25, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will examine the safety and tolerability of ladiratuzumab vedotin (LV) in patients with metastatic breast cancer. LV will be given alone or in combination with trastuzumab.
Conditions
- HER2 Positive Breast Neoplasms
- Hormone Receptor Positive Breast Neoplasms
- Triple Negative Breast Neoplasms
- HER2 Mutations Breast Neoplasms
Interventions
ladiratuzumab vedotinDrug
LV will be given into the vein (IV; intravenously)
TrastuzumabDrug
Trastuzumab will be given by IV every 3 weeks at a dose of 6 mg/kg (the first dose will be 8 mg/kg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: Through 1 month following last dose; up to approximately 2 years
- Incidence of laboratory abnormalitiesTime frame: Through 1 month following last dose; up to approximately 2 years
- Incidence of dose-limiting toxicity (DLT)Time frame: Through 3 weeks after first dose
Locations
38 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Pinnacle Oncology Hematology
Scottsdale, Arizona
UC San Diego / Moores Cancer Center
La Jolla, California
Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California
University of California at San Francisco
San Francisco, California
UCLA Medical Center / David Geffen School of Medicine
Santa Monica, California
Rocky Mountain Cancer Centers - Aurora
Aurora, Colorado
Poudre Valley Health System (PVHS)
Fort Collins, Colorado
Yale Cancer Center
New Haven, Connecticut
The Whittingham Cancer Center / Norwalk Hospital
Norwalk, Connecticut
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Piedmont Cancer Institute
Atlanta, Georgia
University of Chicago Medical Center
Chicago, Illinois
Indiana University Simon Cancer Center
Indianapolis, Indiana
Louisiana State University Health Sciences Center
New Orleans, Louisiana
University of Maryland
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Institute / Wayne State University
Detroit, Michigan
Allina Health Cancer Institute
Minneapolis, Minnesota
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota
Washington University in St Louis
St Louis, Missouri
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
University of New Mexico Cancer Center
Albuquerque, New Mexico
Columbia University Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Weill Cornell Medicine
New York, New York
Wake Forest Baptist Medical Center / Wake Forest University
Winston-Salem, North Carolina
Case Western Reserve University / University Hospitals Cleveland Medical Center
Cleveland, Ohio
The Cleveland Clinic
Cleveland, Ohio
Oregon Health and Science University
Portland, Oregon
Tennessee Oncology-Nashville/Sarah Cannon Research Institute
Nashville, Tennessee
Texas Oncology - Baylor Sammons Cancer Center
Dallas, Texas
Cancer Care Centers of South Texas - HOAST/Texas Oncology
New Braunfels, Texas
Northwest Medical Specialties
Puyallup, Washington
Swedish Cancer Institute
Seattle, Washington
Seattle Cancer Care Alliance / University of Washington
Seattle, Washington
West Virginia University
Morgantown, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.